L’Oréal to acquire majority stake in Medik8

The deal is expected to complete in the coming months.

L’Oréal Groupe has signed a deal to acquire a majority stake in British skincare brand Medik8, expanding its premium skincare portfolio under L’Oréal Luxe.

Private equity firm Inflexion will remain a minority shareholder. Founder Elliot Isaacs will stay on the board, and the current management team will continue to lead the brand.

Known for its Crystal Retinal serum and CSA Philosophy©, Medik8 focuses on science-driven, ingredient-led skincare.

L’Oréal will begin consolidating Medik8 sales after the transaction closes. The agreement includes an option for L’Oréal to acquire the remaining shares.

The deal is expected to complete in the coming months, subject to regulatory approval.